Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaPazopanib in ovarian cancer.Targeted agents and combinations in ovarian cancer: where are we now?Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer.
P2860
Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@en
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@nl
type
label
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@en
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@nl
prefLabel
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@en
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@nl
P2093
P2860
P1433
P1476
Pazopanib and liposomal doxoru ...... rah Cannon Research Institute.
@en
P2093
Chris B Earwood
Cynthia C Chua
Irfan D Firdaus
P2860
P356
10.3109/07357907.2014.998833
P577
2015-01-23T00:00:00Z